Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response

Journal of Hepatology
John M VierlingJean-Pierre Bronowicki

Abstract

Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment with peginterferon/ribavirin. We studied the efficacy of BOC/PR in patients with prior treatment failure, including those with a null response (<2-log10 decline in HCV RNA), to peginterferon/ribavirin. Patients in the control arms of boceprevir Phase 2/3 studies who did not achieve SVR were re-treated with BOC/PR for up to 44 weeks. Patients enrolling >2 weeks after end-of-treatment in the prior study received PR for 4 weeks before adding boceprevir. Of 168 patients enrolled, four discontinued from the PR lead-in and 164 received BOC/PR. Baseline viral load was >800,000 IU/ml in 77% of patients; 62% had HCV genotype 1a, and 10% were cirrhotic. In the ITT analysis (all 168 patients), SVR was achieved in 20 (38%) of 52 patients with prior null response, 57 (67%) of 85 with prior partial response, and 27 (93%) of 29 with prior relapse. In the mITT analysis (164 BOC/PR-treated patients), SVR rates were 41% (20/49), 67% (57/85), and 96% (27/28), respectively. SVR was achieved by 48% of patients with <1-log10 decline in HCV-...Continue Reading

References

Jul 25, 2009·The New England Journal of Medicine·John G McHutchisonUNKNOWN IDEAL Study Team
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Oct 16, 2012·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Steven L FlammFred Poordad

❮ Previous
Next ❯

Citations

Apr 15, 2014·The New England Journal of Medicine·Fred PoordadBarry Bernstein
Nov 15, 2014·Scandinavian Journal of Gastroenterology·Etienne BrochotGilles Duverlie
Feb 28, 2017·Antiviral Research·Guangdi Li, Erik De Clercq
Jun 12, 2014·Expert Review of Clinical Pharmacology·Brian LamZobair Younossi
Dec 4, 2014·World Journal of Gastroenterology : WJG·Veronica BernabucciErica Villa
May 7, 2015·Current Opinion in Organ Transplantation·Bashar A Aqel, Hugo E Vargas
May 24, 2014·Journal of Gastroenterology and Hepatology·Eric J Lawitz, Fernando E Membreno
Feb 3, 2015·Journal of Gastroenterology and Hepatology·Vince Fragomeli, Martin Weltman
Aug 1, 2015·World Journal of Gastroenterology : WJG·Wattana SukeepaisarnjaroenSeng Gee Lim
Sep 17, 2021·Archivum Immunologiae Et Therapiae Experimentalis·Bruno Rivas-SantiagoAdrian Rodriguez-Carlos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.